학술논문
PD-020 Tolerability and activity of second-line tepotinib, a potent and highly selective c-MET inhibitor, in patients with advanced hepatocellular carcinoma previously treated with sorafenib
Document Type
Article
Author
Source
In Annals of Oncology June 2016 27 Supplement 2:ii109-ii109
Subject
Language
ISSN
0923-7534